<DOC>
	<DOCNO>NCT00234975</DOCNO>
	<brief_summary>The purpose study evaluate clinical response safety Kaletra contain antiretroviral treatment regimen HIV positive subject HCV coinfection .</brief_summary>
	<brief_title>Safety Lopinavir/Ritonavir ( Kaletra ) HIV/HCV Co-infected Subjects v Baseline Liver Biopsy Metavir Score</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Documented HIV positive . At least 18 year age . Does exhibit evidence acute illness ( especially acute liver disease , except hepatitis C ) Subject treat active opportunistic infection within 30 day baseline visit . Subject Has Karnofsky Score great equal 70 . Subject require agrees take , duration study , follow medication contraindicate Kaletra : astemizole , terfenadine , midazolam , triazolam , cisapride , certain ergot derivative ( ergotamine , dihydroergotamine , ergonovine , methylergonovine ) , pimozide , propafenone flecainide . Rifampin , potent enzyme inducer , administer study medication , possibility significant decrease Kaletra concentration concurrent administration . The subject agrees take medication , include overthecounter medicine , alcohol , recreational drug herbal preparation without knowledge permission principal investigator . Subject laboratory test within previous three month recent test demonstrate follow : Hemoglobin &gt; 8.0 g/dL ; absolute neutrophil count &gt; 750 cells/mL ; Platelet count &gt; 20,000/mL ; ALT AST &lt; /=10 x upper limit normal ( ULN ) ; Creatinine &lt; 1.5 x ULN ; Triglycerides &lt; /=750 mg/dL . Subjects evidence grade III IV adverse event laboratory abnormality ( except LFTs ) . No exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Lopinavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Phase 4</keyword>
	<keyword>HIV</keyword>
</DOC>